Polyostotic Fibrous Dysplasia: Response to Zoledronic Acid
Main Article Content
Abstract
Fibrous Dysplasia (FD) is a rare developmental bone disorder in which fibro-osseous tissue replaces normal bone tissue. FD can manifest as either monostotic or polyostotic. Polyostotic FD is often associated with McCune-Albright syndrome (MAS). Treatment of FD varies due to its diverse clinical manifestations. Bisphosphonate therapy, with its antiresorptive properties, is commonly used as part of the treatment. Two commonly used bisphosphonates are pamidronate and alendronate. However, literature on the use of intravenous zoledronate is limited. In this report, we share our experience using zoledronate to treat polyostotic fibrous dysplasia in a 10-year-old girl.
Downloads
Article Details
References
Tripathy SK, Swaroop S, Velagada S, Priyadarshini D, Das RR, Satpathy, et al. Response to Zoledronic Acid Infusion in Children With Fibrous Dysplasia. Frontiers in Pediatrics. 2020; 8. https://doi.org/10.3389/fped.2020.582316
Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, de Sanctis C. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune‐Albright syndrome. Acta Paediatrica. 2000; 89(2), 188–193. https://doi.org/10.1111/j.1651-2227.2000.tb01214.x
Ganda K, Seibel MJ. Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases. Osteoporosis International. 2014; 25(2), 777–782. https://doi.org/10.1007/s00198-013-2585-1
Wu D, Ma J, Bao S, Guan H. Continuous effect with long-term safety in zoledronic acid therapy for polyostotic fibrous dysplasia with severe bone destruction. Rheumatology International. 2015; 35(4), 767–772. https://doi.org/10.1007/s00296-014-3132-x
Corsi A, Ippolito E, Robey PG, Riminucci M, Boyde A. Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune–Albright syndrome. Skeletal Radiology, 46(10), 1435–1439. https://doi.org/10.1007/s00256-017-2698-2